# Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

> **NCT02530476** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 17 (actual)

## Conditions studied

- Leukemia
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02530476
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-08
- **Primary completion:** 2019-04-08
- **Final completion:** 2019-04-08
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-03-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02530476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02530476, "Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02530476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*